Treatment of db/db diabetic mice with triptolide: A novel therapy for diabetic nephropathy

Nephrology Dialysis Transplantation

Volumn 25, Issue 11, 2010, Pages 3539-3547

  Gao, Qing ^a   Shen, Wenwen ^a   Qin, Wenwen ^a   Zheng, Chunxia ^a   Zhang, Mingchao ^a   Zeng, Caihong ^a   Wang, Shengyu ^a   Wang, Jianping ^a   Zhu, Xiaodong ^a   Liu, Zhihong ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Albuminuria; Db db mice; DN; Triptolide; Valsartan

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; TRIPTOLIDE; VALSARTAN; CCL2 PROTEIN, MOUSE; DESMIN; DITERPENE; DRUG DERIVATIVE; EPOXIDE; LIPID; MONOCYTE CHEMOTACTIC PROTEIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; PHENANTHRENE DERIVATIVE; REACTIVE OXYGEN METABOLITE; TETRAZOLE DERIVATIVE; VALINE;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD ANALYSIS; BODY WEIGHT; BOWMAN CAPSULE VOLUME; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GLOMERULUS VOLUME; HYPERLIPIDEMIA; KIDNEY HYPERTROPHY; LIVER TOXICITY; LOW DRUG DOSE; MALE; MOUSE; NEPHRITIS; NEPHROTOXICITY; NONHUMAN; OBESITY; ORGAN SIZE; OXIDATIVE STRESS; PODOCYTE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RENAL PROTECTION; TREATMENT DURATION; TREATMENT OUTCOME; URINALYSIS; ANIMAL; BLOOD; C57BL MOUSE; DRUG EFFECT; ELECTRON MICROSCOPY; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; KIDNEY; LIVER; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; T LYMPHOCYTE; ULTRASTRUCTURE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD GLUCOSE; BODY WEIGHT; CHEMOKINE CCL2; DESMIN; DIABETIC NEPHROPATHIES; DITERPENES; EPOXY COMPOUNDS; GLOMERULAR FILTRATION RATE; IMMUNOHISTOCHEMISTRY; KIDNEY; LIPIDS; LIVER; MICE; MICE, INBRED C57BL; MICROSCOPY, ELECTRON; PHENANTHRENES; PODOCYTES; REACTIVE OXYGEN SPECIES; T-LYMPHOCYTES; TETRAZOLES; VALINE;

EID: 79952197634     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq245     Document Type: Article

References (38)

1. Jefferson JA, Shankland SJ, Pichler RH. Proteinuria in diabetic kidney disease: A mechanistic viewpoint. Kidney Int 2008; 74: 22-36 (Pubitemid 351841893)
2. Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008; 57: 1446-1454
3. Rivero A, Mora C, Muros M et al. Pathogenic perspectives for the role of inflammation in diabetic nephropathy. Clin Sci 2009; 116: 479-492
4. Standards of medical care in diabetes-2007. Diabetes Care 2007; 30: S4-S41
5. Han SY, So GA, Jee YH et al. Effect of retinoic acid in experimental diabetic nephropathy. Immunol Cell Biol 2004; 82: 568-576
6. Winer S, Chan Y, Paltser G et al. Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med 2009; 15: 921-929
7. Goldbach-Mansky R, Wilson M, Fleischmann R et al. Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: A randomized trial. Ann Intern Med 2009; 151: 229-240
8. Li LS, Liu ZH. Tripterygium wilfordii on nephritis for the past twenty-five years. Chin J Nephrol Dial Transplant 2003; 12: 246-247(Chinese)
9. Chen ZH, Qin WS, Zeng CH et al. Triptolide reduces proteinuria in experimental membranous nephropathy and protects C5b-9-induced podocyte injuries in vitro. Kidney Int Advance online publication 10 March 2010; doi: 10.1038/ki.2010.41
10. Zheng CX, Chen ZH, Zeng CH et al. Triptolide protects podocytes from puromycinaminonucleoside induced injury in vivo and in vitro. Kidney Int 2008; 74: 596-612
11. Liu ZH, Li SJ, Wu Y et al. Treatment of membranous nephropathy with Tripterygium wilfordii and steroid: A prospective randomized control trial. Chin J Nephrol Dial Transplant 2009; 18: 303-309 (Chinese)
12. Song HX, Gong J, ChenWet al. Effect of triptolide on urinary monocyte chemottractant protein-1 in patients with diabetic nephropathy. Chin J Integrated Traditional West Med 2005; 25: 416-418
13. van den Berg JG, van den Bergh Weerman MA, Assmann KJ et al. Podocyte foot process effacement is not correlated with the level of proteinuria in human glomerulopathies. Kidney Int 2004; 66: 1901-1906 (Pubitemid 41094314)
14. White KE, Bilious RW. Estimation of podocyte number: A comparison of methods. Kidney Int 2004; 66: 663-667 (Pubitemid 38982009)
15. Hummel KP, Dickie MM, Coleman DL. Diabetes, a new mutation in the mouse. Science 1966; 153: 1127
16. Jia ZH, Liu ZH, Zheng JM et al. Combined therapy of rhein and benazepril on the treatment of diabetic nephropathy in db/db mice. Exp Clin Endocrinol Diabetes 2007; 115: 571-576 (Pubitemid 350070926)
17. Silver DL, Jiang XC, Tall AR. Increased high density lipoprotein (HDL), defective hepatic catabolism of ApoA-I and ApoA-II, and decreased ApoA-I mRNA in ob/ob mice. Possible role of leptin in stimulation of HDL turnover. J Biol Chem 1999; 274: 4140-4146
18. Kasai S, Inoue T, Yoshitomi H et al. Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs. J Pharmacol Sci 2008; 108: 40-48
19. Gao Q, Qin WS, Jia ZH et al. Rhein improves renal lesion and ameliorates dyslipidemia in db/db mice with diabetic nephropathy. Planta Medica 2009; 75: 1-7
20. Nishimura S, Manabe I, Nagasaki M et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med 2009; 15: 914-920
21. Tang W, Zhou R, Yang Y et al. Suppression of (5R)-5-hydroxytriptolide (LLDT-8) on allograft rejection in full MHC-mismatched mouse cardiac transplantation. Transplantation 2006; 81: 927-933
22. Tang W, Yang Y, Zhang F et al. Prevention of graft-versus-host disease by a novel immunosuppressant, (5R)-5-hydroxytriptolide (LLDT-8), through expansion of regulatory T cells. Int Immunopharmacol 2005; 5: 1904-1913 (Pubitemid 41586229)
23. Bagby SP. Diabetic nephropathy and proximal tubule ROS: Challenging our glomerulocentricity. Kidney Int 2007; 71: 1199-1202 (Pubitemid 46884264)
24. Hevener AL, Febbraio MA, the Stock Conference Working Group. The 2009 Stock Conference Report: Inflammation, obesity and metabolic disease. Obes Rev [Epub ahead of print] DOI: 10.1111/j.1467- 789X.2009.00691.x
25. Wu YC, Liu ZH, Xiang ZY et al. Obesity-related glomerulopathy: Insights from gene expression profiles of the glomeruli derived from renal biopsy samples. Endocrinology 2006; 147: 44-50
26. Fried LF, Qrchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal diseases: A meta-analysis. Kidney Int 2001; 59: 260-269 (Pubitemid 32055234)
27. Mitsuo Tanimoto, Qiuling Fan, Tomohito Gohda et al. Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice. Metabolism 2004; 53: 1473-1479 (Pubitemid 39410389)
28. Bertelli AA, Migliori M, Panichi Vet al. Resveratrol, a component of wine and grapes, in the prevention of kidney disease. Ann N Y Acad Sci 2002; 957: 230-238 (Pubitemid 34721667)
29. Comper WD, Russo LM. Where does albuminuria come from in diabetic kidney disease? Curr Diab Rep 2008; 8: 477-485
30. Chagnac A, Weinstein T, Korzets A et al. Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol 2000; 278: F817-F822 (Pubitemid 30351084)
31. Matsumoto H, Nakao T, Okada T et al. Insulin resistance contributes to obesity-related proteinuria. Intern Med 2005; 44: 548-553 (Pubitemid 40932826)
32. Ha H, Hwang IA, Park JH et al. Role of reactive oxygen species in the pathogenesis of diabetic nephropathy. Diabetes Res Clin Pract 2008; 82: S42-S45
33. Banba N, Nakamura T, Matsumura M et al. Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int 2000; 58: 684-690 (Pubitemid 30620017)
34. Tesch GH. MCP-1/CCL2: A new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol 2008; 294: F697-F701
35. Liu H, Liu ZH, Chen ZH et al. Triptolide: A potent inhibitor of NF-kappa B in T-lymphocytes. Acta Pharmacol Sin 2000; 21: 782-786
36. Wu Y, Cui J, Bao X et al. Triptolide attenuates oxidative stress, NF- ?B activation and multiple cytokine gene expression in murine peritoneal macrophage. Int J Mol Med 2006; 17: 141-150
37. Wiggins RC. The spectrum of podocytopathies: A unifying view of glomerular diseases. Kidney Int 2007; 71: 1205-1214 (Pubitemid 46884251)
38. Thomas MC, Tikellis C, Burns WM et al. Interactions between renin angiotensin system and advanced glycation in the kidney. J Am Soc Nephrol 2005; 16: 2976-2984 (Pubitemid 44743495)